Parexel reveals strategic plans to ramp up its Indian operations—underscoring India’s emerging prominence as a critical node in …
Parexel reveals strategic plans to ramp up its Indian operations—underscoring India’s emerging prominence as a critical node in …
Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Oncolytics Biotech discloses compelling new pelareorep combination data—in anal and pancreatic cancer cohorts—highlighting durable responses and tolerable safety …
Dogwood kicks off the Phase IIb study of Halneuron®, a non-opioid Nav1.7 inhibitor for chemotherapy-induced neuropathy—marking a critical …
The journal Nature identifies seven transformative technologies for 2025, with self-driving laboratories and advanced immunotherapies set to accelerate …
Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Mereo BioPharma’s Phase 3 study in osteogenesis imperfecta progresses to interim analysis, while alvelestat gains momentum toward EU orphan …
Already a subscriber? Log in